Clinical applications of pulmonary delivery of antibiotics

Advanced Drug Delivery Reviews

Volumn 85, Issue , 2015, Pages 1-6

  Flume, Patrick A ^a   VanDevanter, Donald R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol; Bronchiectasis; Cystic fibrosis; Inhaled antibiotics; Mycobacteria; Pneumocystis

Indexed keywords

AEROSOLS;

BRONCHIECTASIS; CLINICAL APPLICATION; CYSTIC FIBROSIS; MYCOBACTERIA; PNEUMOCYSTIS; PULMONARY DELIVERY; PULMONARY INFECTIONS; STANDARD OF CARES;

ANTIBIOTICS;

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; AZTREONAM LYSINE; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; FLUCLOXACILLIN; GENTAMICIN; PENTAMIDINE; PLACEBO; TOBRAMYCIN; VANCOMYCIN; AEROSOL; ANTIINFECTIVE AGENT;

AEROSOL; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; BURKHOLDERIA INFECTION; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRY POWDER INHALER; ERADICATION THERAPY; HUMAN; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM AVIUM COMPLEX; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; MYCOBACTERIUM INFECTIONS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84930082600     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.009     Document Type: Review

References (90)

1. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
2. LiPuma J.J. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001, 120:118S-123S.
3. Mukhopadhyay S., Staddon G.E., Eastman C., Palmer M., Davies E.R., Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir. Med. 1994, 88:203-211.
4. Laube B.L., Links J.M., LaFrance N.D., Wagner H.N., Rosenstein B.J. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest 1989, 95:822-830.
5. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J. Cyst. Fibros. 2011, 10:54-61.
6. Gibson R.L., Retsch-Bogart G.Z., Oermann C., Milla C., Pilewski J., Daines C., Ahrens R., Leon K., Cohen M., McNamara S., Callahan T.L., Markus R., Burns J.L. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006, 41:656-665.
7. Cystic Fibrosis Foundation Patient Registry. 2012 Annual Data Report Bethesda, Maryland 2013.
8. Amin R., Lam M., Dupuis A., Ratjen F. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr. Pulmonol. 2011, 46:554-558.
9. Ballmann M., Rabsch P., von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998, 53:732-737.
10. Demko C.A., Byard P.J., Davis P.B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 1995, 48:1041-1049.
11. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002, 34:91-100.
12. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 1992, 12:158-161.
13. Hoiby N., Flensborg E.W., Beck B., Friis B., Jacobsen S.V., Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis, Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand. J. Respir. Dis. 1977, 58:65-79.
14. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., Green C.G., Collins J., Farrell P.M. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr. Pulmonol. 2001, 32:277-287.
15. Kozlowska W.J., Bush A., Wade A., Aurora P., Carr S.B., Castle R.A., Hoo A.F., Lum S., Price J., Ranganathan S., Saunders C., Stanojevic S., Stroobant J., Wallis C., Stocks J. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178:42-49.
16. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., Burns J.L., Khan U., Ramsey B.W. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr. Pulmonol. 2012, 47:125-134.
17. Pamukcu A., Bush A., Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 1995, 19:10-15.
18. Parad R.B., Gerard C.J., Zurakowski D., Nichols D.P., Pier G.B. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect. Immun. 1999, 67:4744-4750.
19. Taccetti G., Campana S., Festini F., Mascherini M., Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J. 2005, 26:458-461.
20. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303:2386-2392.
21. Burns J.L., Gibson R.L., McNamara S., Yim D., Emerson J., Rosenfeld M., Hiatt P., McCoy K., Castile R., Smith A.L., Ramsey B.W. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 2001, 183:444-452.
22. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2003, 2:29-34.
23. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., Lubsch L., Hazle L., Sabadosa K., Marshall B. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health,. Am. J. Respir. Crit. Care Med. 2013, 187:680-689.
24. Doring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
25. Geddes D.M. Nebulised therapy and cystic fibrosis. Eur. Respir. Rev. 1997, 7:173-176.
26. Hodson M.E., Penketh A.R., Batten J.C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981, 2:1137-1139.
27. Touw D.J., Brimicombe R.W., Hodson M.E., Heijerman H.G., Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 1995, 8:1594-1604.
28. Smith A.L. Inhaled antibiotic therapy: what drug? What dose? What regimen? What formulation?. J. Cyst. Fibros. 2002, 1:189-193.
29. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., Vasiljev K.M., Borowitz D., Bowman C.M., Marshall B.C., Marshall S., Smith A.L. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group,. N. Engl. J. Med. 1999, 340:23-30.
30. Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001, 120:107S-113S.
31. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178:921-928.
32. Burns J.L., Van Dalfsen J.M., Shawar R.M., Otto K.L., Garber R.L., Quan J.M., Montgomery A.B., Albers G.M., Ramsey B.W., Smith A.L. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis 1999, 179:1190-1196.
33. Hurley M.N., Ariff A.H., Bertenshaw C., Bhatt J., Smyth A.R. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 2012, 11:288-292.
34. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502.
35. Lo D., VanDevanter D.R., Flume P., Smyth A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respir. Med. 2011, 105(Suppl. 2):S9-S17.
36. Hodson M.E., Gallagher C.G., Govan J.R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002, 20:658-664.
37. Schuster A., Haliburn C., Doring G., Goldman M.H. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013, 68:344-350.
38. Rosenfeld M., Emerson J., Accurso F., Armstrong D., Castile R., Grimwood K., Hiatt P., McCoy K., McNamara S., Ramsey B., Wagener J. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr. Pulmonol. 1999, 28:321-328.
39. Rosenfeld M., Ramsey B.W., Gibson R.L. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 2003, 9:492-497.
40. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gerardin M., Brahimi N., Navarro J., Bingen E. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol. 2001, 32:288-292.
41. Frederiksen B., Koch C., Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr. Pulmonol. 1999, 28:159-166.
42. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997, 23:330-335.
43. Ratjen F., Comes G., Paul K., Posselt H.G., Wagner T.O., Harms K. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr. Pulmonol. 2001, 31:13-16.
44. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
45. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., Williams J., Hiatt P., Gibson R.L., Spencer T., Orenstein D., Chatfield B.A., Froh D.K., Burns J.L., Rosenfeld M., Ramsey B.W. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 2011, 165:847-856.
46. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
47. Kun P., Landau L.I., Phelan P.D. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust. Paediatr. J. 1984, 20:43-45.
48. Tramper-Stranders G.A., van der Ent C.K., Molin S., Yang L., Hansen S.K., Rau M.H., Ciofu O., Johansen H.K., Wolfs T.F. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clin. Microbiol. Infect. 2012, 18:567-574.
49. Heinzl B., Eber E., Oberwaldner B., Haas G., Zach M.S. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 2002, 33:32-37.
50. Ferkol T., Rosenfeld M., Milla C.E. Cystic fibrosis pulmonary exacerbations. J. Pediatr. 2006, 148:259-264.
51. Orenstein D.M., Pattishall E.N., Nixon P.A., Ross E.A., Kaplan R.M. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990, 98:1081-1084.
52. Bradley J., McAlister O., Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur. Respir. J. 2001, 17:712-715.
53. Britto M.T., Kotagal U.R., Hornung R.W., Atherton H.D., Tsevat J., Wilmott R.W. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121:64-72.
54. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., Stokes D.C., Wohl M.E., Wagener J.S., Regelmann W.E., Johnson C.A. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J. Pediatr. 2007, 151:134-139. (139 e131).
55. VanDevanter D.R., Wagener J.S., Pasta D.J., Elkin E., Jacobs J.R., Morgan W.J., Konstan M.W. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr. Pulmonol. 2010, 45:1156-1166.
56. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 2010, 182:627-632.
57. Sanders D.B., Bittner R.C., Rosenfeld M., Redding G.J., Goss C.H. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr. Pulmonol. 2011, 46:393-400.
58. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Epidemiol. 2001, 153:345-352.
59. Mayer-Hamblett N., Rosenfeld M., Emerson J., Goss C.H., Aitken M.L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am. J. Respir. Crit. Care Med. 2002, 166:1550-1555.
60. Ellaffi M., Vinsonneau C., Coste J., Hubert D., Burgel P.R., Dhainaut J.F., Dusser D. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2005, 171:158-164.
61. Cystic Fibrosis Foundation Treatment of pulmonary exacerbation of cystic fibrosis. Clinical Practice Guidelines for Cystic Fibrosis 1997.
62. Wagener J.S., Rasouliyan L., VanDevanter D.R., Pasta D.J., Regelmann W.E., Morgan W.J., Konstan M.W. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 2013, 48:666-673.
63. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., Marshall B.C. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 2009, 180:802-808.
64. Stenbit A.E., Bullington W.M., Heh J.L., Flume P.A. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J. Cyst. Fibros. 2013, 12:403-406.
65. LiPuma J. The new microbiology of cystic fibrosis: it takes a community. Thorax 2012, 67:851-852.
66. Ledson M.J., Gallagher M.J., Jackson M., Hart C.A., Walshaw M.J. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002, 57:142-145.
67. Esther C.R., Esserman D.A., Gilligan P., Kerr A., Noone P.G. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J. Cyst. Fibros. 2010, 9:117-123.
68. Tullis D.E., Burns J.L., Retsch-Bogart G.Z., Bresnik M., Henig N.R., Lewis S.A., Lipuma J.J. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J. Cyst. Fibros. 2014, 13:296-305.
69. Smyth A., Walters S. Prophylactic antibiotics for cystic fibrosis. The, Cochrane database of systematic reviews 2003, CD001912.
70. Weaver L.T., Green M.R., Nicholson K., Mills J., Heeley M.E., Kuzemko J.A., Austin S., Gregory G.A., Dux A.E., Davis J.A. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch. Dis. Child. 1994, 70:84-89.
71. Stutman H.R., Lieberman J.M., Nussbaum E., Marks M.I. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Pediatr. 2002, 140:299-305.
72. McShane P.J., Naureckas E.T., Tino G., Strek M.E. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2013, 188:647-656.
73. Barker A.F., Couch L., Fiel S.B., Gotfried M.H., Ilowite J., Meyer K.C., O'Donnell A., Sahn S.A., Smith L.J., Stewart J.O., Abuan T., Tully H., Van Dalfsen J., Wells C.D., Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000, 162:481-485.
74. Orriols R., Roig J., Ferrer J., Sampol G., Rosell A., Ferrer A., Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir. Med. 1999, 93:476-480.
75. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127:1420-1426.
76. Dhar R., Anwar G.A., Bourke S.C., Doherty L., Middleton P., Ward C., Rutherford R.M. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010, 65:553.
77. Murray M.P., Govan J.R., Doherty C.J., Simpson A.J., Wilkinson T.S., Chalmers J.D., Greening A.P., Haslett C., Hill A.T. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011, 183:491-499.
78. Wilson R., Welte T., Polverino E., De Soyza A., Greville H., O'Donnell A., Alder J., Reimnitz P., Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 2013, 41:1107-1115.
79. Crockett A.J., Cranston J.M., Latimer K.M., Alpers J.H. Mucolytics for bronchiectasis. The, Cochrane database of systematic reviews 2001, CD001289.
80. Barker A.F., O'Donnell A.E., Flume P., Thompson P.J., Ruzi J.D., de Gracia J., Boersma W.G., De Soyza A., Shao L., Zhang J., Haas L., Lewis S.A., Leitzinger S., Montgomery A.B., McKevitt M.T., Gossage D., Quittner A.L., O'Riordan T.G. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014, 2:738-749.
81. Evans D.J., Bara A.I., Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. The, Cochrane database of systematic reviews 2007, CD001392.
82. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., Iseman M., Olivier K., Ruoss S., von Reyn C.F., Wallace R.J., Winthrop on behalf of the ATS Mycobacterial Diseases Subcommittee K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007, 175:367-416.
83. Olivier K.N., Shaw P.A., Glaser T.S., Bhattacharyya D., Fleshner M., Brewer C.C., Zalewski C.K., Folio L.R., Siegelman J.R., Shallom S., Park I.K., Sampaio E.P., Zelazny A.M., Holland S.M., Prevots D.R. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann. Am. Thorac. Soc. 2014, 11:30-35.
84. Leoung G.S., Feigal D.W., Montgomery A.B., Corkery K., Wardlaw L., Adams M., Busch D., Gordon S., Jacobson M.A., Volberding P.A., et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N. Engl. J. Med. 1990, 323:769-775.
85. Hirschel B., Lazzarin A., Chopard P., Opravil M., Furrer H.J., Ruttimann S., Vernazza P., Chave J.P., Ancarani F., Gabriel V., et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N. Engl. J. Med. 1991, 324:1079-1083.
86. American Thoracic Society and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005, 171:388-416.
87. Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D., Clementi E., Gonzalez J., Jusserand D., Asfar P., Perrin D., Fieux F., Aubas S., Pneum A.T.G. Comparison of 8 vs 15days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
88. Palmer L.B. Aerosolized antibiotics in critically ill ventilated patients. Curr. Opin. Crit. Care 2009, 15:413-418.
89. Falagas M.E., Siempos I.A., Bliziotis A.Michalopoulos Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit. Care 2006, 10:R123.
90. Fink J.B., Dhand R. Aerosol therapy in mechanically ventilated patients: recent advances and new techniques. Semin. Respir. Crit. Care Med. 2000, 21:183-201.